Project Grant R01AR083469
Award Date
8/1/24
Completion Date
7/31/29
Dollars Obligated
$123K
Federal Grant Program
93.846
Assistance Type
Project Grant
Place of Performance
Kansas City, KS 66160, USA
Similar Awards
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded Vanderbilt University a $393,412 Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to develop engineered cells as agents for treating osteoarthritis. The project aims to leverage advanced cell design platforms to create synthetic receptor-controlled, joint-resident cells that can detect cartilage degeneration and then upregulate the expression of transgenes to promote...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $196,460 Project Grant (CFDA 93.846) to the University of Pittsburgh to test a novel microphysiological system for studying neuro-immune interactions in osteoarthritis pain. The project aims to understand the influence of synovial-like tissue inflammatory molecules on innervating neurons, assess the role of chemokines and neuropeptides on pain and inflammation, and develop a platform for testing...
This $1,288,152 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will fund research to develop a high-throughput screening approach to identify nanoparticles (NPs) capable of targeted delivery to specific cell types in osteoarthritis (OA) joints. The principal investigator, Tufts University School of Medicine, will create a library of DNA-barcoded...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $1,657,392 to the University of Pittsburgh to repurpose FDA-approved drugs for the treatment of osteoarthritis (OA). The project aims to use high-throughput screening in microphysiological models to identify disease-modifying OA drugs (DMOADs) from the existing FDA-approved drug library....
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $618,629 Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to The Regents of the University of Colorado to establish a new "microphysiological joint-on-chip" system. The objective is to create a realistic human joint model that can support mechanistic study of arthritic diseases and rapid testing of candidate treatments. The researchers plan to develop...
This $578,944 federal Project Grant award was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The primary objective is to decipher the genetics of osteoarthritis (OA) susceptibility, heterogeneity, and progression. The research aims to identify new and fine-map known genetic loci associated with OA and total joint replacement, disentangle OA heterogeneity by...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), part of the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $412,610.00 to the Oklahoma Medical Research Foundation (OMRF) to investigate associations between the peripheral blood microbiome and knee osteoarthritis. The key objectives are to determine if baseline peripheral blood bacterial DNA patterns can predict future radiographic and...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $398,415 Project Grant under CFDA 93.846 (Arthritis, Musculoskeletal and Skin Diseases Research) to Regenosine, Inc. for the development of a liposomal adenosine product, RGNA09M, as a disease-modifying regenerative therapy for the treatment and prevention of osteoarthritis. The grant funding will be used to validate analytical methods, establish a CGMP manufacturing process, and produce a 1-liter sterile...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to Trustees of Boston University, doing business as Boston University Medical Campus. The $347,056 grant, awarded on September 20, 2024, will support research into the role of vitamin K in knee osteoarthritis outcomes. The project aims to evaluate blood thresholds of vitamin K associated with structural...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $711,161 Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to Northwestern University. The grant will fund research to define and validate guidelines for interpreting commonly used patient-reported outcome measures (PROMs) for pain and physical function in patients with advanced knee osteoarthritis (OA) receiving medical, rehabilitation, or surgical treatment. The...